ReviewFrontiers in ophthalmology2023
The BVI ISOPURE
Review in Frontiers in ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Visual Outcomes Three and Six Months After Bilateral Implantation of Extended Monofocal Isopure 1.2.3 Lenses.Journal of clinical medicine · 2026Article
- An Update on Intraocular Lens Technology for Presbyopia Correction and Visual Outcomes.Medical sciences (Basel, Switzerland) · 2026Review
- Objective Depth-of-Focus Estimation from Wavefront Measurements After Implantation of an Isofocal Intraocular Lens.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Impact of Intraocular Lens Design on Refractive Endpoint Selection: A Call for a New Paradigm.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Evaluation of Evolux™ Intraocular Lenses in Cataract Surgery: Clinical Outcomes and Patient Satisfaction.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BVI ISOPURE Methods: PubMed, Web of Science, Scopus, and Google Scholar searches were conducted for published research articles featuring the ISOPURE 123 IOL. Results: Excellent uncorrected and corrected binocular distance visual acuity of at least 20/25 can be achieved; uncorrected binocular intermediate vision of 20/25 or better in 81% and 50% at 80 cm and 66 cm, respectively, and 42% binocular near vision of 20/40 or better can be achieved. The defocus curve showed good visual acuity at far and intermediate distances with a depth of focus value of 1.50 D. Photic phenomena are minimal compared to other EDOF IOLs. Excellent contrast sensitivity was maintained compared to a standard monofocal IOL. Conclusion: Studies show that this isofocal optic design IOL provides excellent visual performance for far vision and functional intermediate vision with an increased range of vision with few photic phenomena. This lens is an effective option for providing functional intermediate vision and correcting aphakia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.